Updated:
NeuroOne Medical Technologies
Dave Rosa's NeuroOne Medical Technologies is publicly traded medical device firm developing a single-platform electrode for neural recording and ablation.
NeuroOne Medical Technologies
NeuroOne Medical Technologies was incorporated in Delaware in 2017 and is headquartered in Eden Prairie, Minnesota. The company is led by CEO Dave Rosa. As a publicly traded commercial-stage medical device firm, NeuroOne develops high-definition, thin-film electrodes for recording, stimulating, and ablating brain tissue. Its wealth origin is not a single-family fortune but rather public equity markets, having accessed capital through a 2019 initial public offering on the Nasdaq under the ticker NMTC. The company does not manage familial wealth, nor does it deploy capital into third-party funds. The company's strategy centers on a single core platform: a polyimide-based thin-film electrode technology designed for both short-term diagnostic brain mapping and long-term therapeutic ablation. Current Food and Drug Administration 510(k) clearances cover diagnostic electrode use for recording brain activity for up to 30 days, with a therapeutic ablation system pursuing a separate regulatory pathway. The business model is asset-light, relying on a network of third-party manufacturers for production. Named commercial partners and product releases include a distribution agreement with Zimmer Biomet for the Evo cortical electrode series, signed in 2022. As a specialized neurology device developer, the company's scale is measured in regulatory milestones and product volumes, not assets under management or large clinical teams. A key operational event occurred in June 2023, when NeuroOne announced the first successful commercial cases using its OneRF Ablation system, marking the company's transition from pure diagnostics into therapeutic interventions. The firm maintains its sole office in Minnesota. NeuroOne's structural differentiator is the dual-use nature of its implanted electrode platform. The same thin-film device can monitor brain activity to identify seizure foci and then deliver radiofrequency energy to ablate that tissue without a second implant procedure. This integrated diagnostic-therapeutic approach targets a specific inefficiency in the standard of care where epilepsy patients traditionally require one implant to map seizures and a second surgery to treat them.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Eden Prairie
Corporate office
Eden Prairie, MN, United States
Principals
David Rosa
CEO
Sector focus
Frequently asked questions
Is NeuroOne a family office or a medical device company?
NeuroOne Medical Technologies is a publicly traded, commercial-stage medical device company, not a family office. It was founded in 2017 and completed its initial public offering on Nasdaq in 2019. The firm does not manage personal or institutional capital; its sole focus is developing thin-film electrode technology for the brain.
What is the firm's core technology platform?
The firm's core platform is a polyimide-based thin-film electrode. This platform is designed to be a high-definition recording device for diagnostic use and, in its therapeutic configuration, an ablation tool that uses radiofrequency energy to destroy dysfunctional tissue. The dual-use nature of the electrode is the central idea behind the company's pipeline.
Has NeuroOne received any significant FDA clearances?
NeuroOne has received multiple 510(k) clearances from the U.S. Food and Drug Administration for its cortical electrodes for recording brain activity for under 30 days. Its OneRF Ablation System, which leverages the same electrode technology to create a therapeutic lesion, secured 510(k) clearance in 2023 before its first commercial cases were announced.
Who distributes NeuroOne's products?
NeuroOne entered into a distribution agreement with Zimmer Biomet for its Evo cortical electrode series in 2022. This partnership provides the company with an established commercial sales channel into the neurosurgery market in the United States.
What is the significance of the OneRF Ablation system?
The OneRF Ablation system represents the company's move from a purely diagnostic tool supplier into the therapeutic neurology market. In June 2023, NeuroOne announced the first commercial procedures using this system. The significance for clinicians and patients is a potential pathway to a single-procedure diagnosis and treatment for conditions like drug-resistant epilepsy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: